2020
Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
Cheng H, Luo G, Jin K, Fan Z, Huang Q, Gong Y, Xu J, Yu X, Liu C. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Cancer Medicine 2020, 9: 2153-2159. PMID: 32017404, PMCID: PMC7064028, DOI: 10.1002/cam4.2895.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCD4 Lymphocyte CountCirculating Tumor DNADNA Mutational AnalysisFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMutationNeoplasm StagingPancreatic NeoplasmsPolymerase Chain ReactionPrognosisProto-Oncogene Proteins p21(ras)Retrospective StudiesTime FactorsT-Lymphocytes, RegulatoryConceptsCell-free circulating tumor DNAAdvanced pancreatic cancer patientsPancreatic cancer patientsCirculating regulatory T cellsCirculating T-cell subsetsCA19-9 levelsRegulatory T cellsKRAS mutation statusT cell subsetsTumor-node-metastasisCancer patientsMutation statusTumor DNAKRAS mutationsT cellsAssociated with extremely poor survivalRegulatory T cell levelsAdvanced pancreatic cancerLevels of TregsProportion of TregsAbnormal immune statusCirculating tumor DNAT cell levelsPredicted worse prognosisTumor-node-metastasis stage
2016
Critical role of oncogenic KRAS in pancreatic cancer (Review)
LIU J, JI S, LIANG C, QIN Y, JIN K, LIANG D, XU W, SHI S, ZHANG B, LIU L, LIU C, XU J, NI Q, YU X. Critical role of oncogenic KRAS in pancreatic cancer (Review). Molecular Medicine Reports 2016, 13: 4943-4949. PMID: 27121414, DOI: 10.3892/mmr.2016.5196.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic cancerGenetically engineered mouse modelsPancreatic intraepithelial neoplasiaDevelopment of pancreatic ductal adenocarcinomaFormation of pancreatic intraepithelial neoplasiaProgression of pancreatic ductal adenocarcinomaIntraepithelial neoplasiaHigher mortality rateMutated KRASDuctal adenocarcinomaMouse modelHuman malignanciesKRASKRAS signalingPharmacological inhibitionOncogenic KRASPharmacological targetsMortality rateCancerTargeting KRASMolecular mechanismsProgression